Three Bays Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Three Bays Capital’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-476,367	Closed	-$19.1M	–	17
2018 Q3	$19.1M	Hold	476,367	–	–	2.25%	17
2018 Q2	$13.5M	Buy	476,367 +240,292	+102%	+$5.33M	0.52%	23
2018 Q1	$3.61M	Buy	+236,075	New	+$5.62M	0.25%	21

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Three Bays Capital's MRNS Position: Q4 2018 in Review

Three Bays Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2018, closing a stake of 476,367 shares — an estimated $19.1M sold.

Three Bays Capital first reported a position in MRNS in Q1 2018 and held it in 3 quarters. The position peaked at $19.1M in Q3 2018. 90 funds tracked by Wall St. Rank hold MRNS as of Q4 2018.

Three Bays Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
Three Bays Capital sold 476,367 Marinus Pharmaceuticals, Inc shares in Q4 2018, an estimated $19.1M.
Three Bays Capital first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 3 quarters.
Three Bays Capital's Marinus Pharmaceuticals, Inc position peaked at $19.1M in Q3 2018.
90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2018.

Based on Three Bays Capital's 13F filing for Q4 2018.